Regulus rises as kidney disease therapy shows promise in early-stage trial

Regulus Therapeutics

12/03/2024 10:50

** Shares of Regulus Therapeutics  RGLS.O  rise 65.2% to
$2.28 premarket
    ** Co says that its therapy for autosomal dominant
polycystic kidney disease (ADPKD) in an early-stage trial showed
a response in patients based on levels of polycystins in urine
    ** RGLS says three patients with the highest increases in
polycystins also had reductions in total kidney cyst volume
    ** ADPKD is the most common form of polycystic kidney
disease, which causes numerous cysts to grow in the kidneys, and
may lead to kidney failure
    ** Up to last close, stock up 9.5% in the last 12 months 

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))